The findings in this study strongly suggest that DcR3 plays important roles in tumor progression of human MFH by decoy as well as non-decoy functions and that DcR3 may serve as a potent therapeutic target for human MFH. The gene discussed is TNFRSF6B; the disease is undifferentiated pleomorphic sarcoma.